Safety of tildrakizumab in patients with preexisting metabolic syndrome: Post hoc analysis of 2 phase 3 clinical studies (reSURFACE 1 and reSURFACE 2)

2019 ◽  
Vol 81 (4) ◽  
pp. AB446
Keyword(s):  
Metabolic Syndrome ◽  
Clinical Studies ◽  
Phase 3 ◽  
Post Hoc Analysis ◽  
Post Hoc

scholarly journals Tofacitinib in Patients With Psoriatic Arthritis and Metabolic Syndrome: A Post hoc Analysis of Phase 3 Studies

2020 ◽  
Vol 2 (10) ◽  
pp. 543-554
Author(s):  
Christopher T. Ritchlin ◽  
Jon T. Giles ◽  
Alexis Ogdie ◽  
Juan J. Gomez‐Reino ◽  
Philip Helliwell ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Psoriatic Arthritis ◽  
Phase 3 ◽  
Post Hoc Analysis ◽  
Post Hoc

15938 Tildrakizumab efficacy by metabolic syndrome status in psoriasis: Post hoc analysis of 3-year data from the phase 3 reSURFACE 1 study

2020 ◽  
Vol 83 (6) ◽  
pp. AB51
Author(s):  
Mark G. Lebwohl ◽  
Alice B. Gottlieb ◽  
Alan M. Mendelsohn ◽  
Jeff Parno ◽  
Stephen J. Rozzo ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Phase 3 ◽  
Post Hoc Analysis ◽  
Post Hoc

15950 Tildrakizumab efficacy by metabolic syndrome status in psoriasis: Post hoc analysis of 3-year data from the phase 3 reSURFACE 2 study

2020 ◽  
Vol 83 (6) ◽  
pp. AB164
Author(s):  
Alice B. Gottlieb ◽  
Nehal N. Mehta ◽  
Mark Lebwohl ◽  
Alan M. Mendelsohn ◽  
Jeff Parno ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Phase 3 ◽  
Post Hoc Analysis ◽  
Post Hoc

scholarly journals Tildrakizumab Efficacy by Metabolic Syndrome Status in Psoriasis: Post Hoc Analysis of 3-Year Data from the Phase 3 Resurface 1 And Resurface 2 Studies

2020 ◽  
Vol 4 (5) ◽  
pp. s42
Author(s):  
Mark G Lebwohl ◽  
Nehal N Mehta ◽  
Alice B Gottlieb ◽  
Alan M Mendelsohn
Keyword(s):  
Metabolic Syndrome ◽  
Phase 3 ◽  
Post Hoc Analysis ◽  
Post Hoc

Abstract not available.

Sign in / Sign up

Export Citation Format

Share Document